Skip to main content
Premium Trial:

Request an Annual Quote

Roche Pharma to Use Expression Pathology's Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology said today that Roche will use its Liquid Tissue - SRM technology to identify molecular markers as part of its oncology drug programs.

The Rockville, Md.-based company said that it will provide Roche with multiplexed quantitative assays of cancer signaling pathway proteins and support their activation in formalin-fixed, paraffin-embedded samples for mass spectrometry analysis.

“This new approach to tissue analysis has the potential to dramatically streamline and improve biomarker identification in FFPE samples during clinical development,” said Miro Venturi, senior biomarker and experimental medicine leader at Roche, in a statement.

Over the long term, Roche may use the Expression Pathology platform as "a new way of profiling tumors at the molecular level to improve patient stratification and therefore to advance our discovery of personalized medicines," Venturi added.

Financial terms of the agreement were not released.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.